Hydroxychloroquine Drug Interactions
173Total Interactions
120Severe
36Moderate
0Mild
| Drug | Severity | Summary |
|---|---|---|
| Amifampridine | SEVERE | Both Hydroxychloroquine and Amifampridine prolong the QT interval. Most manufacturers advise avoi... |
| Aminophylline | SEVERE | Aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Amiodarone | SEVERE | Both Hydroxychloroquine and Amiodarone prolong the QT interval. Most manufacturers advise avoidin... |
| Amisulpride | SEVERE | Both Hydroxychloroquine and Amisulpride prolong the QT interval. Most manufacturers advise avoidi... |
| Amphotericin B | SEVERE | Amphotericin B is predicted to cause hypokalaemia (potentially increasing the risk of torsade de ... |
| Anagrelide | SEVERE | Both Hydroxychloroquine and Anagrelide prolong the QT interval. Most manufacturers advise avoidin... |
| Apalutamide | SEVERE | Both Hydroxychloroquine and Apalutamide prolong the QT interval. Most manufacturers advise avoidi... |
| Apomorphine | SEVERE | Both Hydroxychloroquine and Apomorphine prolong the QT interval. Most manufacturers advise avoidi... |
| Aripiprazole | SEVERE | Both Hydroxychloroquine and Aripiprazole prolong the QT interval. Most manufacturers advise avoid... |
| Arsenic trioxide | SEVERE | Both Hydroxychloroquine and Arsenic trioxide prolong the QT interval. Most manufacturers advise a... |
| Artemether | SEVERE | Both Hydroxychloroquine and Artemether prolong the QT interval. Most manufacturers advise avoidin... |
| Artenimol | SEVERE | Both Hydroxychloroquine and Artenimol prolong the QT interval. Most manufacturers advise avoiding... |
| Azithromycin | SEVERE | Azithromycin might increase the risk of serious cardiovascular adverse effects when given with Hy... |
| Beclometasone | SEVERE | Beclometasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Bedaquiline | SEVERE | Both Hydroxychloroquine and Bedaquiline prolong the QT interval. Most manufacturers advise avoidi... |
| Bendroflumethiazide | SEVERE | Bendroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsad... |
| Betamethasone | SEVERE | Betamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Bosutinib | SEVERE | Both Hydroxychloroquine and Bosutinib prolong the QT interval. Most manufacturers advise avoiding... |
| Budesonide | SEVERE | Budesonide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Bumetanide | SEVERE | Bumetanide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Cabozantinib | SEVERE | Both Hydroxychloroquine and Cabozantinib prolong the QT interval. Most manufacturers advise avoid... |
| Ceritinib | SEVERE | Both Hydroxychloroquine and Ceritinib prolong the QT interval. Most manufacturers advise avoiding... |
| Chlorothiazide | SEVERE | Chlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de ... |
| Chlorpromazine | SEVERE | Both Hydroxychloroquine and Chlorpromazine prolong the QT interval. Most manufacturers advise avo... |
| Chlortalidone | SEVERE | Chlortalidone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Citalopram | SEVERE | Both Hydroxychloroquine and Citalopram prolong the QT interval. Most manufacturers advise avoidin... |
| Clarithromycin | SEVERE | Clarithromycin might increase the risk of serious cardiovascular adverse effects when given with ... |
| Clomipramine | SEVERE | Both Hydroxychloroquine and Clomipramine prolong the QT interval. Most manufacturers advise avoid... |
| Crizotinib | SEVERE | Both Hydroxychloroquine and Crizotinib prolong the QT interval. Most manufacturers advise avoidin... |
| Dasatinib | SEVERE | Both Hydroxychloroquine and Dasatinib prolong the QT interval. Most manufacturers advise avoiding... |
| Deflazacort | SEVERE | Deflazacort is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poi... |
| Delamanid | SEVERE | Both Hydroxychloroquine and Delamanid prolong the QT interval. Most manufacturers advise avoiding... |
| Desflurane | SEVERE | Both Hydroxychloroquine and Desflurane prolong the QT interval. Most manufacturers advise avoidin... |
| Dexamethasone | SEVERE | Dexamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Disopyramide | SEVERE | Both Hydroxychloroquine and Disopyramide prolong the QT interval. Most manufacturers advise avoid... |
| Domperidone | SEVERE | Domperidone increases the risk of QT-prolongation when given with Hydroxychloroquine. Manufacture... |
| Dronedarone | SEVERE | Both Hydroxychloroquine and Dronedarone prolong the QT interval. Most manufacturers advise avoidi... |
| Droperidol | SEVERE | Both Hydroxychloroquine and Droperidol prolong the QT interval. Most manufacturers advise avoidin... |
| Efavirenz | SEVERE | Both Hydroxychloroquine and Efavirenz prolong the QT interval. Most manufacturers advise avoiding... |
| Encorafenib | SEVERE | Both Hydroxychloroquine and Encorafenib prolong the QT interval. Most manufacturers advise avoidi... |
| Entrectinib | SEVERE | Both Hydroxychloroquine and Entrectinib prolong the QT interval. Most manufacturers advise avoidi... |
| Eribulin | SEVERE | Both Hydroxychloroquine and Eribulin prolong the QT interval. Most manufacturers advise avoiding ... |
| Erythromycin | SEVERE | Erythromycin might increase the risk of serious cardiovascular adverse effects when given with Hy... |
| Escitalopram | SEVERE | Both Hydroxychloroquine and Escitalopram prolong the QT interval. Most manufacturers advise avoid... |
| Etrasimod | SEVERE | Etrasimod might increase the risk of QT-prolongation when given with Hydroxychloroquine. Manufact... |
| Fingolimod | SEVERE | Fingolimod might increase the risk of QT-prolongation when given with Hydroxychloroquine. Manufac... |
| Fluconazole | SEVERE | Both Hydroxychloroquine and Fluconazole prolong the QT interval. Most manufacturers advise avoidi... |
| Fludrocortisone | SEVERE | Fludrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de... |
| Formoterol | SEVERE | Formoterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Furosemide | SEVERE | Furosemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Glasdegib | SEVERE | Both Hydroxychloroquine and Glasdegib prolong the QT interval. Most manufacturers advise avoiding... |
| Granisetron | SEVERE | Granisetron is predicted to increase the risk of QT-prolongation when given with Hydroxychloroqui... |
| Haloperidol | SEVERE | Both Hydroxychloroquine and Haloperidol prolong the QT interval. Most manufacturers advise avoidi... |
| Hydrochlorothiazide | SEVERE | Hydrochlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsad... |
| Hydrocortisone | SEVERE | Hydrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de ... |
| Hydroflumethiazide | SEVERE | Hydroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade... |
| Hydroxyzine | SEVERE | Both Hydroxychloroquine and Hydroxyzine prolong the QT interval. Most manufacturers advise avoidi... |
| Indacaterol | SEVERE | Indacaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poi... |
| Indapamide | SEVERE | Indapamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Inotuzumab ozogamicin | SEVERE | Both Hydroxychloroquine and Inotuzumab ozogamicin prolong the QT interval. Most manufacturers adv... |
| Isoflurane | SEVERE | Both Hydroxychloroquine and Isoflurane prolong the QT interval. Most manufacturers advise avoidin... |
| Isoprenaline | SEVERE | Isoprenaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de po... |
| Ivabradine | SEVERE | Ivabradine is predicted to increase the risk of torsade de pointes when given with Hydroxychloroq... |
| Ivosidenib | SEVERE | Both Hydroxychloroquine and Ivosidenib prolong the QT interval. Most manufacturers advise avoidin... |
| Lapatinib | SEVERE | Both Hydroxychloroquine and Lapatinib prolong the QT interval. Most manufacturers advise avoiding... |
| Laronidase | SEVERE | Hydroxychloroquine is predicted to decrease the exposure to Laronidase. Manufacturer advises avoi... |
| Lenvatinib | SEVERE | Both Hydroxychloroquine and Lenvatinib prolong the QT interval. Most manufacturers advise avoidin... |
| Levomepromazine | SEVERE | Both Hydroxychloroquine and Levomepromazine prolong the QT interval. Most manufacturers advise av... |
| Mefloquine | SEVERE | Mefloquine is predicted to increase the risk of QT-prolongation when given with Hydroxychloroquin... |
| Methadone | SEVERE | Both Hydroxychloroquine and Methadone prolong the QT interval. Most manufacturers advise avoiding... |
| Methylprednisolone | SEVERE | Methylprednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade... |
| Metolazone | SEVERE | Metolazone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Mizolastine | SEVERE | Mizolastine is predicted to increase the risk of QT-prolongation when given with Hydroxychloroqui... |
| Moxifloxacin | SEVERE | Both Hydroxychloroquine and Moxifloxacin prolong the QT interval. Most manufacturers advise avoid... |
| Nilotinib | SEVERE | Both Hydroxychloroquine and Nilotinib prolong the QT interval. Most manufacturers advise avoiding... |
| Olodaterol | SEVERE | Olodaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Ondansetron | SEVERE | Both Hydroxychloroquine and Ondansetron prolong the QT interval. Most manufacturers advise avoidi... |
| Osilodrostat | SEVERE | Both Hydroxychloroquine and Osilodrostat prolong the QT interval. Most manufacturers advise avoid... |
| Osimertinib | SEVERE | Both Hydroxychloroquine and Osimertinib prolong the QT interval. Most manufacturers advise avoidi... |
| Ozanimod | SEVERE | Ozanimod might increase the risk of QT-prolongation when given with Hydroxychloroquine. Manufactu... |
| Paliperidone | SEVERE | Both Hydroxychloroquine and Paliperidone prolong the QT interval. Most manufacturers advise avoid... |
| Palonosetron | SEVERE | Palonosetron is predicted to increase the risk of QT-prolongation when given with Hydroxychloroqu... |
| Panobinostat | SEVERE | Both Hydroxychloroquine and Panobinostat prolong the QT interval. Most manufacturers advise avoid... |
| Pasireotide | SEVERE | Both Hydroxychloroquine and Pasireotide prolong the QT interval. Most manufacturers advise avoidi... |
| Pazopanib | SEVERE | Both Hydroxychloroquine and Pazopanib prolong the QT interval. Most manufacturers advise avoiding... |
| Penicillamine | SEVERE | Hydroxychloroquine is predicted to increase the risk of haematological toxicity when given with P... |
| Pentamidine | SEVERE | Pentamidine (intravenous or intramuscular) might increase the risk of QT-prolongation when given ... |
| Pimozide | SEVERE | Both Hydroxychloroquine and Pimozide prolong the QT interval. Most manufacturers advise avoiding ... |
| Ponesimod | SEVERE | Ponesimod might increase the risk of QT-prolongation when given with Hydroxychloroquine. Manufact... |
| Prednisolone | SEVERE | Prednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de po... |
| Promethazine | SEVERE | Both Hydroxychloroquine and Promethazine prolong the QT interval. Most manufacturers advise avoid... |
| Quinine | SEVERE | Both Hydroxychloroquine and Quinine prolong the QT interval. Most manufacturers advise avoiding t... |
| Quizartinib | SEVERE | Both Hydroxychloroquine and Quizartinib prolong the QT interval. Most manufacturers advise avoidi... |
| Ranolazine | SEVERE | Both Hydroxychloroquine and Ranolazine prolong the QT interval. Most manufacturers advise avoidin... |
| Ribociclib | SEVERE | Both Hydroxychloroquine and Ribociclib prolong the QT interval. Most manufacturers advise avoidin... |
| Salbutamol | SEVERE | Salbutamol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Salmeterol | SEVERE | Salmeterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Selpercatinib | SEVERE | Both Hydroxychloroquine and Selpercatinib prolong the QT interval. Most manufacturers advise avoi... |
| Sevoflurane | SEVERE | Both Hydroxychloroquine and Sevoflurane prolong the QT interval. Most manufacturers advise avoidi... |
| Siponimod | SEVERE | Siponimod might increase the risk of QT-prolongation when given with Hydroxychloroquine. Manufact... |
| Sorafenib | SEVERE | Both Hydroxychloroquine and Sorafenib prolong the QT interval. Most manufacturers advise avoiding... |
| Sotalol | SEVERE | Both Hydroxychloroquine and Sotalol prolong the QT interval. Most manufacturers advise avoiding t... |
| Sunitinib | SEVERE | Both Hydroxychloroquine and Sunitinib prolong the QT interval. Most manufacturers advise avoiding... |
| Tamoxifen | SEVERE | Tamoxifen increases the risk of retinopathy when given with Hydroxychloroquine. RCOphth guidance ... |
| Terbutaline | SEVERE | Terbutaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poi... |
| Tetrabenazine | SEVERE | Both Hydroxychloroquine and Tetrabenazine prolong the QT interval. Most manufacturers advise avoi... |
| Theophylline | SEVERE | Theophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de po... |
| Tolterodine | SEVERE | Both Hydroxychloroquine and Tolterodine prolong the QT interval. Most manufacturers advise avoidi... |
| Torasemide | SEVERE | Torasemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Toremifene | SEVERE | Both Hydroxychloroquine and Toremifene prolong the QT interval. Most manufacturers advise avoidin... |
| Triamcinolone | SEVERE | Triamcinolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Vamorolone | SEVERE | Vamorolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Vandetanib | SEVERE | Both Hydroxychloroquine and Vandetanib prolong the QT interval. Most manufacturers advise avoidin... |
| Vardenafil | SEVERE | Both Hydroxychloroquine and Vardenafil prolong the QT interval. Most manufacturers advise avoidin... |
| Vemurafenib | SEVERE | Both Hydroxychloroquine and Vemurafenib prolong the QT interval. Most manufacturers advise avoidi... |
| Vernakalant | SEVERE | Both Hydroxychloroquine and Vernakalant prolong the QT interval. Most manufacturers advise avoidi... |
| Vilanterol | SEVERE | Vilanterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Voclosporin | SEVERE | Both Hydroxychloroquine and Voclosporin prolong the QT interval. Most manufacturers advise avoidi... |
| Voriconazole | SEVERE | Both Hydroxychloroquine and Voriconazole prolong the QT interval. Most manufacturers advise avoid... |
| Xipamide | SEVERE | Xipamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointe... |
| Aceclofenac | MODERATE | Aceclofenac (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might... |
| Agalsidase alfa | MODERATE | Hydroxychloroquine is predicted to decrease the effects of Agalsidase alfa. Manufacturer makes no... |
| Agalsidase beta | MODERATE | Hydroxychloroquine is predicted to decrease the exposure to Agalsidase beta. Manufacturer makes n... |
| Antacids | MODERATE | oral Antacids are predicted to decrease the absorption of oral Hydroxychloroquine. Manufacturer a... |
| Aspirin | MODERATE | Aspirin (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might inc... |
| Benzydamine | MODERATE | Benzydamine (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might... |
| Bromfenac | MODERATE | Bromfenac (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might i... |
| Calcium carbonate | MODERATE | oral Calcium carbonate might decrease the absorption of oral Hydroxychloroquine. Manufacturer mak... |
| Celecoxib | MODERATE | Celecoxib (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might i... |
| Cimetidine | MODERATE | Cimetidine is predicted to decrease the clearance of Hydroxychloroquine. Manufacturer makes no re... |
| Dexketoprofen | MODERATE | Dexketoprofen (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use mig... |
| Diclofenac | MODERATE | Diclofenac (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might ... |
| Etodolac | MODERATE | Etodolac (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might in... |
| Etoricoxib | MODERATE | Etoricoxib (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might ... |
| Flurbiprofen | MODERATE | Flurbiprofen (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use migh... |
| Ibuprofen | MODERATE | Ibuprofen (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might i... |
| Indometacin | MODERATE | Indometacin (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might... |
| Kaolin | MODERATE | oral Kaolin is predicted to decrease the absorption of oral Hydroxychloroquine. Manufacturer make... |
| Ketoprofen | MODERATE | Ketoprofen (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might ... |
| Ketorolac | MODERATE | Ketorolac (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might i... |
| Lanthanum | MODERATE | Lanthanum is predicted to decrease the absorption of Hydroxychloroquine. Manufacturer advises sep... |
| Magnesium | MODERATE | oral Magnesium trisilicate is predicted to decrease the absorption of oral Hydroxychloroquine. Ma... |
| Mefenamic acid | MODERATE | Mefenamic acid (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use mi... |
| Meloxicam | MODERATE | Meloxicam (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might i... |
| Nabumetone | MODERATE | Nabumetone (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might ... |
| Naproxen | MODERATE | Naproxen (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might in... |
| Nepafenac | MODERATE | Nepafenac (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might i... |
| Parecoxib | MODERATE | Parecoxib (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might i... |
| Phenazone | MODERATE | Phenazone (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might i... |
| Piroxicam | MODERATE | Piroxicam (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might i... |
| Rabies vaccine | MODERATE | Hydroxychloroquine is predicted to decrease efficacy Rabies vaccine. Manufacturer makes no recomm... |
| Remdesivir | MODERATE | Hydroxychloroquine might decrease the effects of Remdesivir. Manufacturer advises avoid. |
| Sulindac | MODERATE | Sulindac (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might in... |
| Tenoxicam | MODERATE | Tenoxicam (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use might i... |
| Tiaprofenic acid | MODERATE | Tiaprofenic acid (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use ... |
| Tolfenamic acid | MODERATE | Tolfenamic acid (high-dose) might cause ototoxicity, as can Hydroxychloroquine ; concurrent use m... |
| Amikacin | LOW | Both Hydroxychloroquine and Amikacin can increase the risk of ototoxicity. |
| Carboplatin | LOW | Both Hydroxychloroquine and Carboplatin can increase the risk of ototoxicity. |
| Chloroquine | LOW | Both Hydroxychloroquine and Chloroquine can increase the risk of ototoxicity. |
| Cisplatin | LOW | Both Hydroxychloroquine and Cisplatin can increase the risk of ototoxicity. |
| Colistimethate | LOW | Both Hydroxychloroquine and Colistimethate can increase the risk of ototoxicity. |
| Gentamicin | LOW | Both Hydroxychloroquine and Gentamicin can increase the risk of ototoxicity. |
| Neomycin | LOW | Both Hydroxychloroquine and Neomycin can increase the risk of ototoxicity. |
| Netilmicin | LOW | Both Hydroxychloroquine and Netilmicin can increase the risk of ototoxicity. |
| Oxaliplatin | LOW | Both Hydroxychloroquine and Oxaliplatin can increase the risk of ototoxicity. |
| Streptomycin | LOW | Both Hydroxychloroquine and Streptomycin can increase the risk of ototoxicity. |
| Teprotumumab | LOW | Both Hydroxychloroquine and Teprotumumab can increase the risk of ototoxicity. |
| Tobramycin | LOW | Both Hydroxychloroquine and Tobramycin can increase the risk of ototoxicity. |
| Vancomycin | LOW | Both Hydroxychloroquine and Vancomycin can increase the risk of ototoxicity. |
| Vinblastine | LOW | Both Hydroxychloroquine and Vinblastine can increase the risk of ototoxicity. |
| Vincristine | LOW | Both Hydroxychloroquine and Vincristine can increase the risk of ototoxicity. |
| Vindesine | LOW | Both Hydroxychloroquine and Vindesine can increase the risk of ototoxicity. |
| Vinorelbine | LOW | Both Hydroxychloroquine and Vinorelbine can increase the risk of ototoxicity. |
Check Hydroxychloroquine against your patient's full medication list
InteractRx checks all drug combinations at once — built for GP surgery pharmacists.
Use the Free Checker